Skip to main content
SpringerLink
Log in

Translational Potential of Non-coding RNAs for Cardiovascular Disease

  • Chapter
  • First Online:
Non-coding RNAs in Cardiovascular Diseases

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1229))

Abstract

Heart failure is the end result of a variety of cardiovascular disease states. Heart failure remains a challenge to treat, and the incidence continues to rise with an aging population, and increasing rates of diabetes and obesity. Non-coding RNAs, once considered as “junk DNA”, have emerged as powerful transcriptional regulators and potential therapeutic targets for the treatment of heart failure. Different classes of non-coding RNAs exist, including small non-coding RNAs, referred to as microRNAs, and long non-coding RNAs. Both microRNAs and long non-coding RNAs play a role in cardiac development as well as in the pathogenesis of cardiovascular disease, prompting many studies to investigate their role as potential therapeutic targets. Most studies manipulate miRNAs and lncRNAs of interest via antisense oligonucleotides; however, several challenges remain limiting their potential clinical value. As such, viral and non-viral delivery methods are being developed to achieve targeted delivery in vivo.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Braunwald E. The war against heart failure: the Lancet lecture. Lancet. 2015;385(9970):812–24.

    Article  PubMed  Google Scholar 

  2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després J-P, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–e322.

    PubMed  Google Scholar 

  3. Liu L, Eisen HJ. Epidemiology of heart failure and scope of the problem. Cardiol Clin. 2014;32(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  4. Bernardo BC, Blaxall BC. From bench to bedside: new approaches to therapeutic discovery for heart failure. Heart Lung Circ. 2016;25(5):525–34.

    Article  Google Scholar 

  5. Das A, Samidurai A, Salloum FN. Deciphering non-coding RNAs in cardiovascular health and disease. Front Cardiovasc Med. 2018;5:73.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Wadley GD, Lamon S, Alexander SE, McMullen JR, Bernardo BC. Non-coding RNAs regulating cardiac muscle mass. J Appl Physiol (Bethesda, Md: 1985). 2018.

    Google Scholar 

  7. Barwari T, Joshi A, Mayr M. MicroRNAs in cardiovascular disease. J Am Coll Cardiol. 2016;68(23):2577–84.

    Article  CAS  PubMed  Google Scholar 

  8. Bernardo BC, Charchar FJ, Lin RCY, McMullen JR. A MicroRNA guide for clinicians and basic scientists: background and experimental techniques. Heart Lung Circ. 2012;21(3):131–42.

    Article  CAS  PubMed  Google Scholar 

  9. Bernardo BC, Ooi JYY, Lin RCY, McMullen JR. miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart.Future. Med Chem. 2015;7(13):1771–92.

    CAS  Google Scholar 

  10. Hata A. Functions of MicroRNAs in cardiovascular biology and disease. Annu Rev Physiol. 2013;75(1):69–93.

    Article  CAS  PubMed  Google Scholar 

  11. Xiao J, Chen Y-H. MicroRNAs: novel regulators of the heart. J Thorac Dis. 2010;2(1):43–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Gidlöf O, Erlinge D. MicroRNAs in the failing heart – novel therapeutic targets? Scand Cardiovasc J. 2014;48(6):328–34.

    Article  PubMed  CAS  Google Scholar 

  13. Ooi JYY, Bernardo BC, McMullen JR. The therapeutic potential of microRNAs regulated in settings of physiological cardiac hypertrophy. Future Med Chem. 2014;6(2):205–22.

    Article  CAS  PubMed  Google Scholar 

  14. Wronska A, Kurkowska-Jastrzebska I, Santulli G. Application of microRNAs in diagnosis and treatment of cardiovascular disease. Acta Physiol. 2015;213(1):60–83.

    Article  CAS  Google Scholar 

  15. Zhou SS, Jin JP, Wang JQ, Zhang ZG, Freedman JH, Zheng Y, Cai L. miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges. Acta Pharmacol Sin. 2018;39(7):1073–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kumarswamy R, Bauters C, Volkmann I, Maury F, Fetisch J, Holzmann A, Lemesle G, de Groote P, Pinet F, Thum T. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res. 2014;114(10):1569–75.

    Article  CAS  PubMed  Google Scholar 

  17. Kumarswamy R, Thum T. Non-coding RNAs in cardiac remodeling and heart failure. Circ Res. 2013;113(6):676–89.

    Article  CAS  PubMed  Google Scholar 

  18. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011;469(7330):336–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Lv D, Liu J, Zhao C, Sun Q, Zhou Q, Xu J, Xiao J. Targeting microRNAs in cardiac hypertrophy and heart failure. Mini Rev Med Chem. 2015

    Google Scholar 

  20. Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, Stack C, Latimer PA, Olson EN, van Rooij E. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure/clinical perspective. Circulation. 2011;124(14):1537–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Grueter CE, van Rooij E, Johnson BA, DeLeon SM, Sutherland LB, Qi X, Gautron L, Elmquist JK, Bassel-Duby R, Olson EN. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell. 2012;149(3):671–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Bernardo BC, Gao XM, Tham YK, Kiriazis H, Winbanks CE, Ooi JY, Boey EJ, Obad S, Kauppinen S, Gregorevic P, Du XJ, Lin RC, McMullen JR. Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy. PLoS One. 2014;9(2):e90337.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Bernardo BC, Gao XM, Winbanks CE, Boey EJ, Tham YK, Kiriazis H, Gregorevic P, Obad S, Kauppinen S, Du XJ, Lin RC, McMullen JR. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A. 2012;109(43):17615–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bernardo BC, Ooi JYY, Matsumoto A, Tham YK, Singla S, Kiriazis H, Patterson NL, Sadoshima J, Obad S, Lin RCY, McMullen JR. Sex differences in response to miRNA-34a therapy in mouse models of cardiac disease: identification of sex-, disease- and treatment-regulated miRNAs. J Physiol. 2016;594(20):5959–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Eding JE, Demkes CJ, Lynch JM, Seto AG, Montgomery RL, Semus HM, Jackson AL, Isabelle M, Chimenti S, van Rooij E. The efficacy of cardiac anti-miR-208a therapy is stress dependent. Mol Ther. 2017;25(3):694–704.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Cui C, Yang W, Shi J, Zhou Y, Yang J, Cui Q, Zhou Y. Identification and analysis of human sex-biased MicroRNAs. Genomics Proteomics Bioinformatics. 2018;16(3):200–11.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Tsuji M, Kawasaki T, Matsuda T, Arai T, Gojo S, Takeuchi JK. Sexual dimorphisms of mRNA and miRNA in human/murine heart disease. PLoS One. 2017;12(7):e0177988.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Sanchez-Ruderisch H, Queiros AM, Fliegner D, Eschen C, Kararigas G, Regitz-Zagrosek V. Sex-specific regulation of cardiac microRNAs targeting mitochondrial proteins in pressure overload. Biol Sex Differ. 2019;10(1):8.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Gomes CPC, Spencer H, Ford KL, Michel LYM, Baker AH, Emanueli C, Balligand JL, Devaux Y, Cardiolinc network. The function and therapeutic potential of Long non-coding RNAs in cardiovascular development and disease. Mol Ther Nucleic Acids. 2017;8:494–507.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Greco S, Salgado Somoza A, Devaux Y, Martelli F. Long noncoding RNAs and cardiac disease. Antioxid Redox Signal. 2018;29(9):880–901.

    Article  CAS  PubMed  Google Scholar 

  31. Hermans-Beijnsberger S, van Bilsen M, Schroen B. Long non-coding RNAs in the failing heart and vasculature. Non-coding RNA Res. 2018;3(3):118–30.

    Article  CAS  Google Scholar 

  32. Hobuss L, Bar C, Thum T. Long non-coding RNAs: at the heart of cardiac dysfunction? Front Physiol. 2019;10:30.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Shen S, Jiang H, Bei Y, Xiao J, Li X. Long non-coding RNAs in cardiac remodeling. Cell Physiol Biochem. 2017;41(5):1830–7.

    Article  CAS  PubMed  Google Scholar 

  34. Castanotto D, Lin M, Kowolik C, Wang L, Ren XQ, Soifer HS, Koch T, Hansen BR, Oerum H, Armstrong B, Wang Z, Bauer P, Rossi J, Stein CA. A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells. Nucleic Acids Res. 2015;43(19):9350–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Frieden M, Christensen SM, Mikkelsen ND, Rosenbohm C, Thrue CA, Westergaard M, Hansen HF, Orum H, Koch T. Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res. 2003;31(21):6365–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Micheletti R, Plaisance I, Abraham BJ, Sarre A, Ting CC, Alexanian M, Maric D, Maison D, Nemir M, Young RA, Schroen B, Gonzalez A, Ounzain S, Pedrazzini T. The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci Transl Med. 2017;9(395)

    Google Scholar 

  37. Viereck J, Kumarswamy R, Foinquinos A, Xiao K, Avramopoulos P, Kunz M, Dittrich M, Maetzig T, Zimmer K, Remke J, Just A, Fendrich J, Scherf K, Bolesani E, Schambach A, Weidemann F, Zweigerdt R, de Windt LJ, Engelhardt S, Dandekar T, Batkai S, Thum T. Long noncoding RNA Chast promotes cardiac remodeling. Sci Transl Med. 2016;8(326):326ra322.

    Article  CAS  Google Scholar 

  38. Piccoli MT, Gupta SK, Viereck J, Foinquinos A, Samolovac S, Kramer FL, Garg A, Remke J, Zimmer K, Batkai S, Thum T. Inhibition of the cardiac fibroblast-enriched lncRNA Meg3 prevents cardiac fibrosis and diastolic dysfunction. Circ Res. 2017;121(5):575–83.

    Article  CAS  PubMed  Google Scholar 

  39. Miyoshi N, Wagatsuma H, Wakana S, Shiroishi T, Nomura M, Aisaka K, Kohda T, Surani MA, Kaneko-Ishino T, Ishino F. Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q. Genes Cells. 2000;5(3):211–20.

    Article  CAS  PubMed  Google Scholar 

  40. Zhang X, Rice K, Wang Y, Chen W, Zhong Y, Nakayama Y, Zhou Y, Klibanski A. Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology. 2010;151(3):939–47.

    Article  CAS  PubMed  Google Scholar 

  41. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, Pinto YM. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106(6):1035–9.

    Article  CAS  PubMed  Google Scholar 

  42. Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail. 2012;14(2):147–54.

    Article  CAS  PubMed  Google Scholar 

  43. Ovchinnikova ES, Schmitter D, Vegter EL, Ter Maaten JM, Valente MA, Liu LC, van der Harst P, Pinto YM, de Boer RA, Meyer S, Teerlink JR, O’Connor CM, Metra M, Davison BA, Bloomfield DM, Cotter G, Cleland JG, Mebazaa A, Laribi S, Givertz MM, Ponikowski P, van der Meer P, van Veldhuisen DJ, Voors AA, Berezikov E. Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail. 2016;18(4):414–23.

    Article  CAS  PubMed  Google Scholar 

  44. Vegter EL, Schmitter D, Hagemeijer Y, Ovchinnikova ES, van der Harst P, Teerlink JR, O’Connor CM, Metra M, Davison BA, Bloomfield D, Cotter G, Cleland JG, Givertz MM, Ponikowski P, van Veldhuisen DJ, van der Meer P, Berezikov E, Voors AA, Khan MA. Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. Int J Cardiol. 2016;224:231–9.

    Article  PubMed  Google Scholar 

  45. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?Circulation. Research. 2012;110(3):483–95.

    CAS  Google Scholar 

  46. Xu J, Zhao J, Evan G, Xiao C, Cheng Y, Xiao J. Circulating microRNAs: novel biomarkers for cardiovascular diseases. J Mol Med (Berl). 2012;90(8):865–75.

    Article  CAS  Google Scholar 

  47. Wang G-K, Zhu J-Q, Zhang J-T, Li Q, Li Y, He J, Qin Y-W, Jing Q. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31(6):659–66.

    Article  PubMed  CAS  Google Scholar 

  48. Wang R, Li N, Zhang Y, Ran Y, Pu J. Circulating MicroRNAs are promising novel biomarkers of acute myocardial infarction. Intern Med. 2011;50(17):1789–95.

    Article  CAS  PubMed  Google Scholar 

  49. Viereck J, Thum T. Circulating noncoding RNAs as biomarkers of cardiovascular disease and injury. Circ Res. 2017;120(2):381–99.

    Article  CAS  PubMed  Google Scholar 

  50. Vausort M, Wagner DR, Devaux Y. Long noncoding RNAs in patients with acute myocardial infarction. Circ Res. 2014;115(7):668–77.

    Article  CAS  PubMed  Google Scholar 

  51. Yin Q, Wu A, Liu M. Plasma Long non-coding RNA (lncRNA) GAS5 is a new biomarker for coronary artery disease. Med Sci Monit. 2017;23:6042–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. de Gonzalo-Calvo D, Kenneweg F, Bang C, Toro R, van der Meer RW, Rijzewijk LJ, Smit JW, Lamb HJ, Llorente-Cortes V, Thum T. Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes. Sci Rep. 2016;6:37354.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Gao L, Liu Y, Guo S, Yao R, Wu L, Xiao L, Wang Z, Liu Y, Zhang Y. Circulating long noncoding RNA HOTAIR is an essential mediator of acute myocardial infarction. Cell Physiol Biochem. 2017;44(4):1497–508.

    CAS  PubMed  Google Scholar 

  54. Zhang Y, Sun L, Xuan L, Pan Z, Li K, Liu S, Huang Y, Zhao X, Huang L, Wang Z, Hou Y, Li J, Tian Y, Yu J, Han H, Liu Y, Gao F, Zhang Y, Wang S, Du Z, Lu Y, Yang B. Reciprocal changes of circulating Long non-coding RNAs ZFAS1 and CDR1AS predict acute myocardial infarction. Sci Rep. 2016;6:22384.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Yan Y, Zhang B, Liu N, Qi C, Xiao Y, Tian X, Li T, Liu B. Circulating long noncoding RNA UCA1 as a novel biomarker of acute myocardial infarction. Biomed Res Int. 2016;2016:8079372.

    PubMed  PubMed Central  Google Scholar 

  56. Xuan L, Sun L, Zhang Y, Huang Y, Hou Y, Li Q, Guo Y, Feng B, Cui L, Wang X, Wang Z, Tian Y, Yu B, Wang S, Xu C, Zhang M, Du Z, Lu Y, Yang BF. Circulating long non-coding RNAs NRON and MHRT as novel predictive biomarkers of heart failure. J Cell Mol Med. 2017;21(9):1803–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Chakraborty C, Sharma AR, Sharma G, Doss CGP, Lee S-S. Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine. Mol Ther Nucleic Acids. 2017;8:132–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368(18):1685–94.

    Article  CAS  PubMed  Google Scholar 

  59. Sassi Y, Avramopoulos P, Ramanujam D, Gruter L, Werfel S, Giosele S, Brunner AD, Esfandyari D, Papadopoulou AS, De Strooper B, Hubner N, Kumarswamy R, Thum T, Yin X, Mayr M, Laggerbauer B, Engelhardt S. Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling. Nat Commun. 2017;8(1):1614.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008;105(35):13027–32.

    Article  PubMed  PubMed Central  Google Scholar 

  61. McMullen JR, Bernardo BC. Inhibition of miR-29 protects against cardiac hypertrophy and fibrosis: new insight for the role of miR-29 in the heart. Non-coding RNA Investig. 2018;2:3.

    Article  Google Scholar 

  62. Slabakova E, Culig Z, Remsik J, Soucek K. Alternative mechanisms of miR-34a regulation in cancer. Cell Death Dis. 2017;8(10):e3100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Ooi JYY, Bernardo BC, Singla S, Patterson NL, Lin RCY, McMullen JR. Identification of miR-34 regulatory networks in settings of disease and antimiR-therapy: implications for treating cardiac pathology and other diseases. RNA Biol. 2017;14(5):500–13.

    Article  PubMed  Google Scholar 

  64. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence. 2012;3(1):1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Matkovich SJ, Hu Y, Dorn GW. Regulation of cardiac microRNAs by cardiac microRNAs. Circ Res. 2013;113(1):62–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Patrick DM, Montgomery RL, Qi X, Obad S, Kauppinen S, Hill JA, van Rooij E, Olson EN. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest. 2010;120(11):3912–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456(7224):980–4.

    Article  CAS  PubMed  Google Scholar 

  68. McMullen JR, Drew BG. Long non-coding RNAs (lncRNAs) in skeletal and cardiac muscle: potential therapeutic and diagnostic targets? Clin Sci. 2016;130(24):2245–56.

    Article  CAS  Google Scholar 

  69. Lucas T, Dimmeler S. RNA therapeutics for treatment of cardiovascular diseases: promises and challenges. Circ Res. 2016;119(7):794–7.

    Article  CAS  PubMed  Google Scholar 

  70. Holdt LM, Beutner F, Scholz M, Gielen S, Gabel G, Bergert H, Schuler G, Thiery J, Teupser D. ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arterioscler Thromb Vasc Biol. 2010;30(3):620–7.

    Article  CAS  PubMed  Google Scholar 

  71. Zhao B, Lu YL, Yang Y, Hu LB, Bai Y, Li RQ, Zhang GY, Li J, Bi CW, Yang LB, Hu C, Lei YH, Wang QL, Liu ZM. Overexpression of lncRNA ANRIL promoted the proliferation and migration of prostate cancer cells via regulating let-7a/TGF-beta1/Smad signaling pathway. Cancer Biomark. 2018;21(3):613–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Klattenhoff CA, Scheuermann JC, Surface LE, Bradley RK, Fields PA, Steinhauser ML, Ding H, Butty VL, Torrey L, Haas S, Abo R, Tabebordbar M, Lee RT, Burge CB, Boyer LA. Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell. 2013;152(3):570–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Zangrando J, Zhang L, Vausort M, Maskali F, Marie PY, Wagner DR, Devaux Y. Identification of candidate long non-coding RNAs in response to myocardial infarction. BMC Genomics. 2014;15:460.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Lennox KA, Behlke MA. Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res. 2016;44(2):863–77.

    Article  CAS  PubMed  Google Scholar 

  75. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152(6):1298–307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Wang K, Long B, Zhou LY, Liu F, Zhou QY, Liu CY, Fan YY, Li PF. CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation. Nat Commun. 2014;5:3596.

    Article  PubMed  CAS  Google Scholar 

  77. Wang K, Sun T, Li N, Wang Y, Wang JX, Zhou LY, Long B, Liu CY, Liu F, Li PF. MDRL lncRNA regulates the processing of miR-484 primary transcript by targeting miR-361. PLoS Genet. 2014;10(7):e1004467.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  78. Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med. 2017;9(1):60.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Biglino G, Caputo M, Rajakaruna C, Angelini G, van Rooij E, Emanueli C. Modulating microRNAs in cardiac surgery patients: novel therapeutic opportunities? Pharmacol Ther. 2017;170:192–204.

    Article  CAS  PubMed  Google Scholar 

  80. Kwekkeboom RF, Lei Z, Doevendans PA, Musters RJ, Sluijter JP. Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges. Clin Sci. 2014;127(6):351–65.

    Article  CAS  Google Scholar 

  81. Bass-Stringer S, Bernardo BC, May CN, Thomas CJ, Weeks KL, McMullen JR. Adeno-associated virus gene therapy: translational Progress and future prospects in the treatment of heart failure. Heart Lung Circ. 2018;27(11):1285–300.

    Article  PubMed  Google Scholar 

  82. Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther. 2008;15(23):1550–7.

    Article  CAS  PubMed  Google Scholar 

  83. Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, Hajjar RJ. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res. 2014;114(1):101–8.

    Article  CAS  PubMed  Google Scholar 

  84. Jeong D, Yoo J, Lee P, Kepreotis SV, Lee A, Wahlquist C, Brown BD, Kho C, Mercola M, Hajjar RJ. miR-25 tough decoy enhances cardiac function in heart failure. Mol Ther. 2018;26(3):718–29.

    Article  CAS  PubMed  Google Scholar 

  85. Krol J, Busskamp V, Markiewicz I, Stadler MB, Ribi S, Richter J, Duebel J, Bicker S, Fehling HJ, Schubeler D, Oertner TG, Schratt G, Bibel M, Roska B, Filipowicz W. Characterizing light-regulated retinal microRNAs reveals rapid turnover as a common property of neuronal microRNAs. Cell. 2010;141(4):618–31.

    Article  CAS  PubMed  Google Scholar 

  86. Winbanks CE, Beyer C, Hagg A, Qian H, Sepulveda PV, Gregorevic P. miR-206 represses hypertrophy of myogenic cells but not muscle Fibers via inhibition of HDAC4. PLoS ONE. 2013;8(9):e73589.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Xie J, Ameres SL, Friedline R, Hung JH, Zhang Y, Xie Q, Zhong L, Su Q, He R, Li M, Li H, Mu X, Zhang H, Broderick JA, Kim JK, Weng Z, Flotte TR, Zamore PD, Gao G. Long-term, efficient inhibition of microRNA function in mice using rAAV vectors. Nat Methods. 2012;9(4):403–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Wang F, Fang Q, Chen C, Zhou L, Li H, Yin Z, Wang Y, Zhao CX, Xiao X, Wang DW. Recombinant Adeno-associated virus-mediated delivery of MicroRNA-21-3p lowers hypertension. Mol Ther Nucleic Acids. 2018;11:354–66.

    Article  CAS  PubMed  Google Scholar 

  89. Bernardo BC, Gregorevic P, Ritchie RH, McMullen JR. Generation of microRNA-34 sponges and tough decoys for the heart: developments and challenges. Front Pharmacol Transl Pharmacol. 2018;9:1090.

    Article  CAS  Google Scholar 

  90. Wang X, Searle AK, Hohmann JD, Liu AL, Abraham M-K, Palasubramaniam J, Lim B, Yao Y, Wallert M, Yu E, Chen Y-C, Peter K. Dual-targeted theranostic delivery of miRs arrests abdominal aortic aneurysm development. Mol Ther. 2018;26(4):1056–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Schafer F, Wagner J, Knau A, Dimmeler S, Heckel A. Regulating angiogenesis with light-inducible AntimiRs. Angew Chem Int Ed Engl. 2013;52(51):13558–61.

    Article  PubMed  CAS  Google Scholar 

  92. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Investig. 2005;115(8):2108–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Nie JJ, Qiao B, Duan S, Xu C, Chen B, Hao W, Yu B, Li Y, Du J, Xu FJ. Unlockable nanocomplexes with self-accelerating nucleic acid release for effective staged gene therapy of cardiovascular diseases. Adv Mater. 2018;30(31):e1801570.

    Article  PubMed  CAS  Google Scholar 

  94. Seif-Naraghi SB, Singelyn JM, Salvatore MA, Osborn KG, Wang JJ, Sampat U, Kwan OL, Strachan GM, Wong J, Schup-Magoffin PJ, Braden RL, Bartels K, DeQuach JA, Preul M, Kinsey AM, DeMaria AN, Dib N, Christman KL. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. J Transl Med. 2013;5(173):173ra125.

    Google Scholar 

  95. Wang LL, Liu Y, Chung JJ, Wang T, Gaffey AC, Lu M, Cavanaugh CA, Zhou S, Kanade R, Atluri P, Morrisey EE, Burdick JA. Sustained miRNA delivery from an injectable hydrogel promotes cardiomyocyte proliferation and functional regeneration after ischaemic injury. Nat Biomed Eng. 2017;1(12):983–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Di Mauro V, Iafisco M, Salvarani N, Vacchiano M, Carullo P, Ramirez-Rodriguez GB, Patricio T, Tampieri A, Miragoli M, Catalucci D. Bioinspired negatively charged calcium phosphate nanocarriers for cardiac delivery of MicroRNAs. Nanomedicine (Lond). 2016;11(8):891–906.

    Article  CAS  Google Scholar 

  97. Miragoli M, Ceriotti P, Iafisco M, Vacchiano M, Salvarani N, Alogna A, Carullo P, Ramirez-Rodríguez GB, Patrício T, Esposti LD, Rossi F, Ravanetti F, Pinelli S, Alinovi R, Erreni M, Rossi S, Condorelli G, Post H, Tampieri A, Catalucci D. Inhalation of peptide-loaded nanoparticles improves heart failure. Sci Transl Med. 2018;10(424)

    Google Scholar 

  98. Chang H, Yi B, Ma R, Zhang X, Zhao H, Xi Y. CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo. Sci Rep. 2016;6:22312.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Julie R. McMullen at Baker Heart & Diabetes Institute for proofreading the manuscript. The authors acknowledge funding support from the Sir Edward Dunlop Medical Research Foundation (to J.Y.Y.O and B.C.B). B.C.B is supported by an Alice Baker and Eleanor Shaw Fellowship (The Baker Foundation, Melbourne, Australia).

Competing Financial Interests

The authors declare no competing financial interests.

Author information

Authors and Affiliations

  1. Baker Heart and Diabetes Institute, Melbourne, VIC, Australia

    Jenny Y. Y. Ooi & Bianca C. Bernardo

  2. Department of Diabetes, Central Clinical School, Monash University, Clayton, VIC, Australia

    Jenny Y. Y. Ooi & Bianca C. Bernardo

  3. Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia

    Bianca C. Bernardo

Authors
  1. Jenny Y. Y. Ooi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bianca C. Bernardo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bianca C. Bernardo .

Editor information

Editors and Affiliations

  1. Institute of Cardiovascular Sciences, School of Life Science, Shanghai University, Shanghai, China

    Junjie Xiao

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ooi, J.Y.Y., Bernardo, B.C. (2020). Translational Potential of Non-coding RNAs for Cardiovascular Disease. In: Xiao, J. (eds) Non-coding RNAs in Cardiovascular Diseases. Advances in Experimental Medicine and Biology, vol 1229. Springer, Singapore. https://doi.org/10.1007/978-981-15-1671-9_21

Download citation

Publish with us

Policies and ethics

Search

Navigation